Patients taking glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used to treat Type 2 diabetes and obesity, have a significantly lower risk of developing noninfectious uveitis compared with patients not taking the medication. This…
Patients taking glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used to treat Type 2 diabetes and obesity, have a significantly lower risk of developing noninfectious uveitis compared with patients not taking the medication. This…